DCOY - Salarius Pharmaceuticals, Inc.

0.5825
-0.075   -12.790%

Share volume: 364,896
Last Updated: 03-05-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.31%

PREVIOUS CLOSE
CHG
CHG%
$0.66
-0.07
-0.11%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
9%
Profitability 8%
Dept financing 3%
Liquidity 58%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-11.88%
1 Month
-25.31%
3 Months
-29.82%
6 Months
-87.47%
1 Year
-42.89%
2 Year
-89.29%
Key data
Stock price
$0.58
P/E Ratio 
0.00
DAY RANGE
$0.57 - $0.64
EPS 
-$4.81
52 WEEK RANGE
$0.43 - $7.10
52 WEEK CHANGE
-$44.52
MARKET CAP 
1.871 M
YIELD 
N/A
SHARES OUTSTANDING 
5.862 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
1.66
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$114,970
AVERAGE 30 VOLUME 
$169,609
Company detail
CEO: David J. Arthur
Region: US
Website: salariuspharma.com
Employees: 20
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company is headquartered in Houston, Texas.

Recent news